Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE39.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots37.4100/ 1
- Ask / Lots41.8600/ 1
- Open / Previous Close38.0300 / 39.0000
- Day Range
- 52 Week Range
- Volume461,884
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 1316 | 38.03 |
| 09:34 ET | 100 | 37.725 |
| 09:38 ET | 1255 | 38.25 |
| 09:39 ET | 600 | 38.48 |
| 09:41 ET | 600 | 38.2 |
| 09:43 ET | 1555 | 37.97 |
| 09:45 ET | 500 | 37.88 |
| 09:48 ET | 200 | 37.84 |
| 09:50 ET | 200 | 37.61 |
| 09:52 ET | 495 | 37.94 |
| 09:54 ET | 100 | 38.15 |
| 09:57 ET | 200 | 38.08 |
| 09:59 ET | 205 | 38.4 |
| 10:01 ET | 389 | 38.51 |
| 10:03 ET | 400 | 38.33 |
| 10:06 ET | 256 | 38.43 |
| 10:08 ET | 689 | 38.46 |
| 10:10 ET | 1617 | 38.86 |
| 10:12 ET | 1215 | 38.94 |
| 10:14 ET | 800 | 38.89 |
| 10:15 ET | 790 | 38.905 |
| 10:17 ET | 500 | 39.08 |
| 10:19 ET | 600 | 39.23 |
| 10:21 ET | 100 | 39.23 |
| 10:24 ET | 389 | 39.155 |
| 10:26 ET | 500 | 39.27 |
| 10:28 ET | 300 | 39.22 |
| 10:30 ET | 1500 | 39.01 |
| 10:32 ET | 413 | 39.048 |
| 10:35 ET | 200 | 39.03 |
| 10:37 ET | 375 | 39.14 |
| 10:39 ET | 405 | 39.36 |
| 10:42 ET | 100 | 39.395 |
| 10:44 ET | 200 | 39.42 |
| 10:46 ET | 2134 | 39.61 |
| 10:48 ET | 200 | 39.635 |
| 10:50 ET | 1900 | 39.51 |
| 10:51 ET | 800 | 39.19 |
| 10:53 ET | 2870 | 39.6 |
| 10:57 ET | 500 | 39.87 |
| 11:00 ET | 702 | 39.97 |
| 11:02 ET | 341 | 39.93 |
| 11:04 ET | 268 | 39.96 |
| 11:06 ET | 6186 | 39.925 |
| 11:08 ET | 760 | 39.95 |
| 11:09 ET | 430 | 40.04 |
| 11:11 ET | 100 | 40.1 |
| 11:13 ET | 100 | 40.04 |
| 11:15 ET | 289 | 40.02 |
| 11:18 ET | 1100 | 40.12 |
| 11:20 ET | 100 | 40.26 |
| 11:22 ET | 100 | 40.17 |
| 11:24 ET | 333 | 40.1 |
| 11:29 ET | 200 | 40.07 |
| 11:31 ET | 407 | 40.1 |
| 11:33 ET | 200 | 40.23 |
| 11:36 ET | 100 | 40.165 |
| 11:38 ET | 300 | 40.1345 |
| 11:40 ET | 1100 | 40.2 |
| 11:42 ET | 400 | 40.165 |
| 11:44 ET | 501 | 40.135 |
| 11:45 ET | 200 | 40.16 |
| 11:49 ET | 1753 | 40.245 |
| 11:51 ET | 100 | 40.285 |
| 11:54 ET | 700 | 40.25 |
| 11:58 ET | 1856 | 40.32 |
| 12:00 ET | 400 | 40.295 |
| 12:02 ET | 550 | 40.227 |
| 12:03 ET | 100 | 40.3 |
| 12:05 ET | 1000 | 40.24 |
| 12:12 ET | 100 | 40.24 |
| 12:14 ET | 603 | 40.26 |
| 12:16 ET | 816 | 40.23 |
| 12:18 ET | 703 | 40.32 |
| 12:20 ET | 819 | 40.37 |
| 12:21 ET | 1293 | 40.315 |
| 12:23 ET | 700 | 40.25 |
| 12:25 ET | 709 | 40.25 |
| 12:27 ET | 100 | 40.29 |
| 12:30 ET | 376 | 40.3219 |
| 12:32 ET | 820 | 40.28 |
| 12:34 ET | 10175 | 40.23 |
| 12:36 ET | 1700 | 40.225 |
| 12:38 ET | 200 | 40.28 |
| 12:41 ET | 854 | 40.26 |
| 12:43 ET | 1175 | 40.32 |
| 12:45 ET | 1426 | 40.5 |
| 12:48 ET | 600 | 40.6 |
| 12:50 ET | 633 | 40.52 |
| 12:57 ET | 8524 | 40.4 |
| 12:59 ET | 5857 | 40.4 |
| 01:01 ET | 300 | 40.52 |
| 01:08 ET | 200 | 40.53 |
| 01:10 ET | 300 | 40.56 |
| 01:12 ET | 300 | 40.54 |
| 01:14 ET | 400 | 40.5 |
| 01:15 ET | 3060 | 40.56 |
| 01:19 ET | 200 | 40.72 |
| 01:21 ET | 500 | 40.6885 |
| 01:24 ET | 700 | 40.75 |
| 01:26 ET | 900 | 40.77 |
| 01:30 ET | 200 | 40.76 |
| 01:32 ET | 200 | 40.83 |
| 01:33 ET | 3010 | 40.905 |
| 01:35 ET | 1304 | 40.69 |
| 01:37 ET | 429 | 40.76 |
| 01:39 ET | 200 | 40.755 |
| 01:42 ET | 200 | 40.76 |
| 01:44 ET | 700 | 40.795 |
| 01:46 ET | 2200 | 41.02 |
| 01:48 ET | 2574 | 40.885 |
| 01:50 ET | 457 | 40.975 |
| 01:51 ET | 100 | 40.9267 |
| 01:53 ET | 1997 | 41 |
| 01:57 ET | 1000 | 40.9 |
| 02:00 ET | 100 | 40.915 |
| 02:02 ET | 570 | 40.86 |
| 02:04 ET | 3779 | 40.65 |
| 02:06 ET | 625 | 40.52 |
| 02:08 ET | 1659 | 40.66 |
| 02:09 ET | 1821 | 40.86 |
| 02:13 ET | 805 | 40.85 |
| 02:15 ET | 700 | 40.815 |
| 02:18 ET | 105 | 40.83 |
| 02:20 ET | 200 | 40.87 |
| 02:22 ET | 1000 | 40.98 |
| 02:24 ET | 10086 | 40.65 |
| 02:27 ET | 100 | 40.66 |
| 02:29 ET | 831 | 40.56 |
| 02:31 ET | 100 | 40.49 |
| 02:33 ET | 200 | 40.34 |
| 02:36 ET | 4644 | 40.36 |
| 02:38 ET | 100 | 40.325 |
| 02:40 ET | 2455 | 40.28 |
| 02:42 ET | 300 | 40.33 |
| 02:44 ET | 700 | 40.25 |
| 02:45 ET | 500 | 40.27 |
| 02:47 ET | 200 | 40.2951 |
| 02:49 ET | 200 | 40.26 |
| 02:51 ET | 200 | 40.25 |
| 02:56 ET | 3613 | 39.99 |
| 02:58 ET | 1727 | 40.085 |
| 03:00 ET | 1101 | 40.12 |
| 03:02 ET | 1000 | 40.07 |
| 03:03 ET | 200 | 40.04 |
| 03:05 ET | 8666 | 40.235 |
| 03:07 ET | 1148 | 40.06 |
| 03:09 ET | 1008 | 40.1 |
| 03:14 ET | 654 | 40.14 |
| 03:16 ET | 200 | 40.12 |
| 03:18 ET | 319 | 40.103 |
| 03:20 ET | 309 | 40.115 |
| 03:21 ET | 10014 | 39.955 |
| 03:23 ET | 4421 | 40.06 |
| 03:25 ET | 1600 | 39.925 |
| 03:27 ET | 2875 | 39.6 |
| 03:30 ET | 3231 | 39.73 |
| 03:32 ET | 2310 | 39.725 |
| 03:34 ET | 2354 | 39.795 |
| 03:36 ET | 1986 | 39.69 |
| 03:38 ET | 3878 | 39.76 |
| 03:39 ET | 2029 | 39.73 |
| 03:41 ET | 2182 | 39.73 |
| 03:43 ET | 3411 | 39.505 |
| 03:45 ET | 700 | 39.515 |
| 03:48 ET | 4069 | 39.35 |
| 03:50 ET | 6235 | 39.185 |
| 03:52 ET | 7322 | 39.27 |
| 03:54 ET | 2562 | 39.265 |
| 03:56 ET | 5319 | 39.05 |
| 03:57 ET | 5955 | 38.9 |
| 03:59 ET | 49073 | 39 |
May 28, 2024
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD, from 7:30AM ET on Tuesday May 28, 2024 by Dow Jones
7:30AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD, from 7:30AM ET on Tuesday May 28, 2024 by Dow Jones
7:30AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 2.2B | -19.1x | --- |
Iovance Biotherapeutics Inc | 2.2B | -4.5x | --- |
CG Oncology Inc | 2.1B | -28.3x | --- |
Celldex Therapeutics Inc | 2.3B | -12.7x | --- |
Janux Therapeutics Inc | 2.1B | -35.3x | --- |
Rocket Pharmaceuticals Inc | 2.0B | -8.4x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark McKenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.04 |
Book Value | $7.86 |
P/E Ratio | -19.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
